Understanding the reasons behind the low utilisation of thrombolysis in stroke

Australasian Medical Journal

Volumn 6, Issue 3, 2013, Pages 152-163

  Eissa, Ashraf ^a   Krass, Ines ^a   Levi, Christopher ^b   Sturm, Jonathan ^c   Ibrahim, Rabsima ^d   Bajorek, Beata ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

^c GOSFORD HOSPITAL   (Australia)

^d BLACKTOWN HOSPITAL   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Alteplase; Cerebrovascular accident; Stroke; Thrombolysis; Tissue plasminogen activator (tpa)

Indexed keywords

ENOXAPARIN; HEPARIN;

ADOLESCENT; ADULT; AGED; BRAIN ISCHEMIA; CHILD; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MECHANICAL THROMBECTOMY; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; THERAPY DELAY;

EID: 84875640903     PISSN: 18361935     EISSN: None     Source Type: Journal    
DOI: 10.4066/AMJ.2013.1607     Document Type: Review

References (30)

1. Australian Public Assessment Report for Alteplase 2011, Therapeutic Goods Administration [website]. http://www.tga.gov.au/ (accessed February 2012).
2. Clinical Guidelines for Stroke Management 2010. Melbourne: National Stroke Foundation.
3. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke. 2007; 38: 1655-1711.
4. Guidelines for Management of Ischaemic Stroke update 2009. The European Stroke Organization (ESO) [website]. http://www.eso-stroke.org (accessed Dec 2012).
5. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29.
6. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995 Dec 14;333(24):1581-7.
7. IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012 Jun 23;379(9834):2352-63.
8. National Stroke Audit - Acute Services Clinical Audit Report 2011. Melbourne: National Stroke Foundation.
9. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009 Aug;40(8):2945-8.
10. Rudd AG, Hoffman A, Grant R, Campbell JT, Lowe D; Intercollegiate Working Party for Stroke. Stroke thrombolysis in England, Wales and Northern Ireland: how much do we do and how much do we need? J Neurol Neurosurg Psychiatry. 2011 Jan;82(1):14-9.
11. F.A.S.T campaign. National Stroke Foundation, Australia [website]. http://www.strokefoundation.com.au (accessed Mar 2012).
12. Wang MY, Lavine SD, Soukiasian H, Tabrizi R, Levy ML, Giannotta SL. Treating stroke as a medical emergency: a survey of resident physicians' attitudes toward "brain attack" and carotid endarterectomy. Neurosurgery. 2001 May;48(5):1109-15; discussion 1115-7.
13. Quain DA, Parsons MW, Loudfoot AR, Spratt NJ, Evans MK, Russell ML, Royan AT, Moore AG, Miteff F, Hullick CJ, Attia J, McElduff P, Levi CR. Improving access to acute stroke therapies: a controlled trial of organised pre-hospital and emergency care. Med J Aust. 2008 Oct 20;189(8):429-33.
14. Lindsberg PJ, Häppölä O, Kallela M, Valanne L, Kuisma M, Kaste M. Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment. Neurology. 2006 Jul 25;67(2):334-6.
15. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke. 2005 Aug;36(8):1776-81.
16. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001 Apr 24;56(8):1015-20.
17. Actilyse. European Agency for the Evaluation of Medicinal products. UK Medicines and Healthcareproducts Regulatory Agency (MHRA) and the European Medicines Agency (EMEA). [website]. http://emc.medicines.org.uk (accessed Dec 2012).
18. Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of > or = 80 versus < 80 years of age--a systematic review across cohort studies. Age Ageing. 2006 Nov;35(6):572-80.
19. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM; Cleveland Clinic Health System Stroke Quality Improvement Team. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2004 Mar;61(3):346-50.
20. Moser DK, Kimble LP, Alberts MJ, Alonzo A, Croft JB, Dracup K, Evenson KR, Go AS, Hand MM, Kothari RU, Mensah GA, Morris DL, Pancioli AM, Riegel B, Zerwic JJ. Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on cardiovascular nursing and stroke council. Circulation. 2006 Jul 11;114(2):168-82.
21. Mosley I, Nicol M, Donnan G, Patrick I, Dewey H. Stroke symptoms and the decision to call for an ambulance. Stroke. 2007 Feb;38(2):361-6.
22. Heiss WD. The concept of the penumbra: can it be translated to stroke management? Int J Stroke. 2010 Aug;5(4):290-5.
23. Davis SM, Donnan GA. MR mismatch and thrombolysis: appealing but validation required. Stroke. 2009 Aug;40(8):2910.
24. Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND), Clinical trials [website]. http://clinicaltrials.gov/ct2/show/NCT00887328 (accessed Mar 2012).
25. Kwan J, Hand P, Sandercock P. Improving the efficiency of delivery of thrombolysis for acute stroke: a systematic review. QJM. 2004 May;97(5):273-9.
26. Kleindorfer D, Khoury J, Broderick JP, Rademacher E, Woo D, Flaherty ML, Alwell K, Moomaw CJ, Schneider A, Pancioli A, Miller R, Kissela BM. Temporal trends in public awareness of stroke: warning signs, risk factors, and treatment. Stroke. Stroke. 2009 Jul;40(7):2502-6.
27. Mangum SA, Kraenow KR, Narducci WA. Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J Am Pharm Assoc. 2003;43:50-55.
28. Fagan SC, Zarowitz BJ, Robert S. "Brain attack": an indication for thrombolysis? Ann Pharmacother. 1992 Jan;26(1):73-80.
29. National Regional Profile. Australian Bureau of Statistics [website]. http://www.abs.gov.au (accessed Mar 2012).
30. O'Brien W, Crimmins D, Donaldson W, Risti R, Clarke TA, Whyte S, Sturm J. FASTER (Face, Arm, Speech, Time, Emergency Response): experience of Central Coast Stroke Services implementation of a pre-hospital notification system for expedient management of acute stroke. J Clin Neurosci. 2012 Feb;19(2):241-5.